Evidence map›Paper›PMID 38367982›Full record

ArticleRMD open2024

Adenosine metabolic signature in circulating CD4+ T cells predicts remission in rheumatoid arthritis.

Philip M Brown, Amy E Anderson, Najib Naamane, Dennis W Lendrem, Ann W Morgan, John D Isaacs, Arthur G Pratt

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Philip M BrownTranslational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.ORCID 0000-0002-3271-3596
Amy E AndersonTranslational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.
Najib NaamaneTranslational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.
Dennis W LendremTranslational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.
Ann W MorganLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
John D IsaacsTranslational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.
Arthur G PrattTranslational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK arthur.pratt@newcastle.ac.uk.ORCID 0000-0002-9909-8209
NIHR Newcastle Biomedical Research Centre · GBNewcastle University · GBUniversity of Leeds · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

objectivesLong-term outcomes in rheumatoid arthritis (RA) depend on early and effective disease control. Methotrexate (MTX) remains the first-line disease modifying therapy, however there are no biomarkers with which to identify those most likely to achieve remission. To address this unmet need we explored metabolic pathways involved in MTX mechanism of action within circulating CD4+T cells in a cohort of treatment naive patients with early RA.

methodsPurified CD4+T cells were isolated from peripheral blood of 68 patients with early RA commencing MTX. The expression of a range of putative MTX metabolism and mechanism of action targets were explored by flow-cytometry and transcriptional analysis. From these data significant predictors of Disease Activity Score 28-C reactive protein (DAS28-CRP) remission (<2.4 at 6 months) were determined by logistic regression (clinical; flow-cytometry data) and linear modelling (gene expression data).

resultsLow baseline DAS28-CRP was associated with remission at 6 months (p=0.02). Expression of the ectonucleotidase CD39, involved in ATP-ADP conversion during adenosine synthesis, was higher on CD4+CD25 High regulatory T cells at baseline in those achieving remission (molecules of equivalent fluorescence 1264 vs 847; p=0.007). Expression of other adenosine signalling elements in CD4+T cells were also upregulated at baseline in patients achieving remission:

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAdenosineBiomarkersCD4-Positive T-LymphocytesC-Reactive ProteinHumansMethotrexateTreatment OutcomeAdenosineAntirheumatic AgentsBiomarkersC-Reactive ProteinMethotrexatemethotrexaterheumatoid arthritistherapeutics

Identifiers

PMID38367982
PMCPMC10875551
OpenAlexW4391896799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.